The Trump administration is preparing 100% tariffs on some imported medicines and is modifying tariffs on metals.

The administration of American President Donald Trump intends to impose a 100% tariff on patented drugs imported from pharmaceutical companies that have not entered into agreements with the U.S. government to reduce prices.

According to a draft document obtained by CNBC, patented drugs and their active ingredients will be taxed, but manufacturers will have the option to avoid these taxes if they move production to the U.S. or negotiate agreements with the administration. The proposal is not final and it is not known when it will be officially announced, but some sources suggest that the decision could be communicated as early as Thursday. Since November, several major pharmaceutical companies, such as Eli Lilly, Pfizer, and Novo Nordisk, have signed agreements to reduce drug prices, being exempt from tariffs for three years.

The draft also provides for a 20% tariff for companies that relocate their production to the U.S., with an increase up to 100% over four years. Generic drugs will not be affected by these tariffs, and companies that negotiate with the Department of Health and Human Services will be exempt.

At the same time, a complete review of the tariffs imposed on metals also aims to counteract the practices of companies that try to "artificially manipulate" their production costs to resell at lower prices in the United States. Specifically, finished products that contain a significant proportion of steel, aluminum, or copper will now be taxed at 25% of their total value, rather than 50% of the proportion of metals they contain.